Brain-Computer Interfaces (Bci)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Regional Abnormality of Functional Connectivity Is Associated with Clinical Manifestations in Individuals with Intractable Focal
www.nature.com/scientificreports OPEN Regional abnormality of functional connectivity is associated with clinical manifestations in individuals with intractable focal epilepsy Yasuo Nakai1*, Hiroki Nishibayashi1, Tomohiro Donishi2, Masaki Terada3, Naoyuki Nakao1 & Yoshiki Kaneoke2 We explored regional functional connectivity alterations in intractable focal epilepsy brains using resting-state functional MRI. Distributions of the network parameters (corresponding to degree and eigenvector centrality) measured at each brain region for all 25 patients were signifcantly diferent from age- and sex-matched control data that were estimated by a healthy control dataset (n = 582, 18–84 years old). The number of abnormal regions whose parameters exceeded the mean + 2 SD of age- and sex-matched data for each patient were associated with various clinical parameters such as the duration of illness and seizure severity. Furthermore, abnormal regions for each patient tended to have functional connections with each other (mean ± SD = 58.6 ± 20.2%), the magnitude of which was negatively related to the quality of life. The abnormal regions distributed within the default mode network with signifcantly higher probability (p < 0.05) in 7 of 25 patients. We consider that the detection of abnormal regions by functional connectivity analysis using a large number of control datasets is useful for the numerical assessment of each patient’s clinical conditions, although further study is necessary to elucidate etiology-specifc abnormalities. Approximately 25% of epilepsy patients are medically intractable 1. For these patients, various types of brain surgeries have been performed to improve their quality of life (QOL) by reducing seizure frequency2. However, long-term outcomes, such as the seizure freedom rate, have been stagnating, and treatment of intractable focal epilepsy is still challenging 3. -
Neural Lace" Company
5 Neuroscience Experts Weigh in on Elon Musk's Mysterious "Neural Lace" Company By Eliza Strickland (/author/strickland-eliza) Posted 12 Apr 2017 | 21:15 GMT Elon Musk has a reputation as the world’s greatest doer. He can propose crazy ambitious technological projects—like reusable rockets for Mars exploration and hyperloop tunnels for transcontinental rapid transit—and people just assume he’ll pull it off. So his latest venture, a new company called Neuralink that will reportedly build brain implants both for medical use and to give healthy people superpowers, has gotten the public excited about a coming era of consumerfriendly neurotech. Even neuroscientists who work in the field, who know full well how difficult it is to build working brain gear that passes muster with medical regulators, feel a sense of potential. “Elon Musk is a person who’s going to take risks and inject a lot of money, so it will be exciting to see what he gets up to,” says Thomas Oxley, a neural engineer who has been developing a medical brain implant since 2010 (he hopes to start its first clinical trial in 2018). Neuralink is still mysterious. An article in The Wall Street Journal (https://www.wsj.com/articles/elonmusklaunches neuralinktoconnectbrainswithcomputers1490642652) announced the company’s formation and first hires, while also spouting vague verbiage about “cranial computers” that would Image: iStockphoto serve as “a layer of artificial intelligence inside the brain.” So IEEE Spectrum asked the experts about what’s feasible in this field, and what Musk might be planning. -
Neural Dust: Ultrasonic Biological Interface
Neural Dust: Ultrasonic Biological Interface Dongjin (DJ) Seo Electrical Engineering and Computer Sciences University of California at Berkeley Technical Report No. UCB/EECS-2018-146 http://www2.eecs.berkeley.edu/Pubs/TechRpts/2018/EECS-2018-146.html December 1, 2018 Copyright © 2018, by the author(s). All rights reserved. Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. To copy otherwise, to republish, to post on servers or to redistribute to lists, requires prior specific permission. Neural Dust: Ultrasonic Biological Interface by Dongjin Seo A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Engineering - Electrical Engineering and Computer Sciences in the Graduate Division of the University of California, Berkeley Committee in charge: Professor Michel M. Maharbiz, Chair Professor Elad Alon Professor John Ngai Fall 2016 Neural Dust: Ultrasonic Biological Interface Copyright 2016 by Dongjin Seo 1 Abstract Neural Dust: Ultrasonic Biological Interface by Dongjin Seo Doctor of Philosophy in Engineering - Electrical Engineering and Computer Sciences University of California, Berkeley Professor Michel M. Maharbiz, Chair A seamless, high density, chronic interface to the nervous system is essential to enable clinically relevant applications such as electroceuticals or brain-machine interfaces (BMI). Currently, a major hurdle in neurotechnology is the lack of an implantable neural interface system that remains viable for a patient's lifetime due to the development of biological response near the implant. -
Neurotechnologies and Brain Computer Interface
From Technologies to Market Sample Neurotechnologies and brain computer interface Market and Technology analysis 2018 LIST OF COMPANIES MENTIONED IN THIS REPORT 240+ slides of market and technology analysis Abbott, Ad-tech, Advanced Brain Monitoring, AdvaStim, AIST, Aleva Neurotherapeutics, Alphabet, Amazon, Ant Group, ArchiMed, Artinis Medical Systems, Atlas Neuroengineering, ATR, Beijing Pins Medical, BioSemi, Biotronik, Blackrock Microsystems, Boston Scientific, Brain products, BrainCo, Brainscope, Brainsway, Cadwell, Cambridge Neurotech, Caputron, CAS Medical Systems, CEA, Circuit Therapeutics, Cirtec Medical, Compumedics, Cortec, CVTE, Cyberonics, Deep Brain Innovations, Deymed, Dixi Medical, DSM, EaglePicher Technologies, Electrochem Solutions, electroCore, Elmotiv, Endonovo Therapeutics, EnerSys, Enteromedics, Evergreen Medical Technologies, Facebook, Flow, Foc.us, G.Tec, Galvani Bioelectronics, General Electric, Geodesic, Glaxo Smith Klein, Halo Neurosciences, Hamamatsu, Helius Medical, Technologies, Hitachi, iBand+, IBM Watson, IMEC, Integer, Integra, InteraXon, ISS, Jawbone, Kernel, LivaNova, Mag and More, Magstim, Magventure, Mainstay Medical, Med-el Elektromedizinische Geraete, Medtronic, Micro Power Electronics, Micro Systems Technologies, Micromed, Microsoft, MindMaze, Mitsar, MyBrain Technologies, Natus, NEC, Nemos, Nervana, Neurable, Neuralink, NeuroCare, NeuroElectrics, NeuroLutions, NeuroMetrix, Neuronetics, Neuronetics, Neuronexus, Neuropace, Neuros Medical, Neuroscan, NeuroSigma, NeuroSky, Neurosoft, Neurostar, Neurowave, -
Participant Guide
Participant Guide Get Enough Sleep Session Focus Getting enough sleep can help you prevent or delay type 2 diabetes. This session we will talk about: z Why sleep matters z Some challenges of getting enough sleep and ways to cope with them You will also make a new action plan! Tips: ✓ Go to bed and get up at the same time each day. This helps your body get on a schedule. ✓ Follow a bedtime routine that helps you wind down. Participant Guide: Get Enough Sleep 2 Jenny’s Story Jenny is at risk for type 2 diabetes. Her doctor asks her if she gets at least 7 hours of sleep each night. Jenny laughs. “Are you serious?” she asks. “I’m lucky if I get 5 hours.” Jenny usually doesn’t have much trouble falling asleep. But she often has to use the bathroom in the early morning. This gets her thinking about all the things she needs to do the next day. Plus, her husband’s breathing is loud. Both of these things make it hard for Jenny to fall back to sleep. She often lies awake for hours. These days, Jenny drinks less water and avoids caffeine in the evening. She makes a list of things to do the next day. Then she sets it aside. Jenny rarely needs to get up to use the bathroom during the night. If she does, she breathes deeply to help her get back to sleep. She also runs a fan to cover up the sound of her husband’s breathing. Jenny is closer to getting 7 hours of sleep a night. -
A Study Finalised to the Development of a BCI for Locked-In Subjects Based on Single Trial
POLITECNICO DI TORINO Corso di Laurea in Ingegneria Biomedica Tesi di Laurea Magistrale Habit and neural fatigue: a study finalised to the development of a BCI for Locked-In subjects based on Single Trial EEG Relatore Prof.ssa Gabriella Olmo Irene Rechichi Correlatore: Ing. Vito De Feo Luglio 2019 A Lorenzo per il rumore e il silenzio Abstract Author: Irene RECHICHI The Locked-In Syndrome is a medical condition regarding awake subjects that are aware and conscious but are not able to communicate verbally and physically; they are subjected to complete paralysis of almost all voluntary skeletal muscles, except for those who regulate vertical eye movements and eye-blinking. This condition is also described as pseudocoma and is mainly due to ventral pontine injuries. The future aim of this research project is to develop a BCI for single trial EEG analysis, that would be able to recognize specific patterns in the electrical activity of the brain, called movement-related cortical potentials. Among these event-related po- tentials, those of great interest for this study are readiness potentials, that generate when volitional movements are performed. The research work was divided into two parts: the experimental data collection and subsequent data analysis; habit and per- ceived tiredness can be listed among the factors that affect the readiness potential. In this preparatory study, the aim was to find evidence of that. Experimental data collection took several months and involved healthy subjects of age 20 to 60 and one injured subject, in minimally conscious state. The subjects underwent completely voluntary and semivoluntary tasks. The event-related potentials were extracted by simple averaging of the trials; the epochs ended with muscular activation. -
Electrocorticography Evidence of Tactile Responses in Visual Cortices
UvA-DARE (Digital Academic Repository) Electrocorticography Evidence of Tactile Responses in Visual Cortices Gaglianese, A.; Branco, M.P.; Groen, I.I.A.; Benson, N.C.; Vansteensel, M.J.; Murray, M.M.; Petridou, N.; Ramsey, N.F. DOI 10.1007/s10548-020-00783-4 Publication date 2020 Document Version Final published version Published in Brain Topography License CC BY Link to publication Citation for published version (APA): Gaglianese, A., Branco, M. P., Groen, I. I. A., Benson, N. C., Vansteensel, M. J., Murray, M. M., Petridou, N., & Ramsey, N. F. (2020). Electrocorticography Evidence of Tactile Responses in Visual Cortices. Brain Topography, 33(5), 559–570. https://doi.org/10.1007/s10548-020-00783-4 General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:03 Oct 2021 Brain Topography (2020) 33:559–570 https://doi.org/10.1007/s10548-020-00783-4 ORIGINAL PAPER Electrocorticography Evidence of Tactile Responses in Visual Cortices Anna Gaglianese1,2,3 · Mariana P. -
Towards a UK Neurotechnology Strategy
Towards a UK Neurotechnology Strategy A UK ecosystem for Neurotechnology: Development, commercial exploitation and societal adoption Prof. Keith Mathieson (Chair) | Prof. Tim Denison (Co-chair) | Dr. Charlie Winkworth-Smith 1 Towards a UK Neurotechnology Strategy Towards a UK Neurotechnology Strategy Contents Executive Summary 05 A UK Eco-System for Neurotechnology: Development, Commercial Exploitation and Societal Adoption 06 The UK 08 Our Proposed Approach 12 Case Study: Retinal Prosthetics 15 Uses of Neurotechnology 18 Bioelectronic Medicine 18 Brain-Computer Interfaces 19 Human Cognitive Augmentation 21 Development of New Neurotechnologies Provides Non-Pharmaceutical Alternatives to Chronic Pain Relief 22 Overview of the UK Neurotechnology Landscape 24 Opportunities for the UK 29 Steering Group 30 We will create a shared vision for the UK to be a world leader in neurotechnology. 2 1 https://www.internationalbraininitiative.org/ 3 Executive Summary Recent funding initiatives have changed the global neurotechnology landscape, with the US, China, Japan, the EU, Canada and Australia all investing at scale in 10 year+ programmes. In particular, the US has seen an investment of $1.7 billion since 2014 in their national programme1. The resultant rapid maturation of the academic research has led to sophisticated clinical devices capable of treating neurodegenerative conditions in patients and to a burgeoning commercial sector. The UK, with its outstanding neuroscience, medical and engineering expertise, has an exciting opportunity to make a valuable contribution to the leadership of this international effort. Vision: In response to this opportunity our vision is to bring together the existing strengths and form a cohesive UK eco-system to accelerate commercial and economic opportunities from neurotechnology science and engineering research. -
Sleep Apnea Sleep Apnea
Health and Safety Guidelines 1 Sleep Apnea Sleep Apnea Normally while sleeping, air is moved at a regular rhythm through the throat and in and out the lungs. When someone has sleep apnea, air movement becomes decreased or stops altogether. Sleep apnea can affect long term health. Types of sleep apnea: 1. Obstructive sleep apnea (narrowing or closure of the throat during sleep) which is seen most commonly, and, 2. Central sleep apnea (the brain is causing a change in breathing control and rhythm) Obstructive sleep apnea (OSA) About 25% of all adults are at risk for sleep apnea of some degree. Men are more commonly affected than women. Other risk factors include: 1. Middle and older age 2. Being overweight 3. Having a small mouth and throat Down syndrome Because of soft tissue and skeletal alterations that lead to upper airway obstruction, people with Down syndrome have an increased risk of obstructive sleep apnea. Statistics show that obstructive sleep apnea occurs in at least 30 to 75% of people with Down syndrome, including those who are not obese. In over half of person’s with Down syndrome whose parents reported no sleep problems, sleep studies showed abnormal results. Sleep apnea causing lowered oxygen levels often contributes to mental impairment. How does obstructive sleep apnea occur? The throat is surrounded by muscles that are active controlling the airway during talking, swallowing and breathing. During sleep, these muscles are much less active. They can fall back into the throat, causing narrowing. In most people this doesn’t affect breathing. However in some the narrowing can cause snoring. -
Towards a Passive BCI to Induce Lucid Dream Morgane Hamon, Emma Chabani, Philippe Giraudeau
Towards a Passive BCI to Induce Lucid Dream Morgane Hamon, Emma Chabani, Philippe Giraudeau To cite this version: Morgane Hamon, Emma Chabani, Philippe Giraudeau. Towards a Passive BCI to Induce Lucid Dream. Journée Jeunes Chercheurs en Interfaces Cerveau-Ordinateur et Neurofeedback 2019 (JJC- ICON ’19), Mar 2019, Villeneuve d’Ascq, France. hal-02108903 HAL Id: hal-02108903 https://hal.archives-ouvertes.fr/hal-02108903 Submitted on 29 Apr 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. TOWARDS A PASSIVE BCI TO INDUCE LUCID DREAM JJC-ICON ’19 Morgane Hamon Emma Chabani Philippe Giraudeau Ullo Institut du Cerveau et de la Moelle épinière Inria La Rochelle, France Paris, France Bordeaux, France [email protected] [email protected] [email protected] April 29, 2019 ABSTRACT Lucid dreaming (LD) is a phenomenon during which the person is aware that he/she dreaming and is able to control the dream content. Studies have shown that only 20% of people can experience lucid dreams on a regular basis. However, LD frequency can be increased through induction techniques. External stimulation technique relies on the ability to integrate external information into the dream content. -
Non-Invasive Neurostimulation Methods for Acute and Preventive Migraine Treatment—A Narrative Review
Journal of Clinical Medicine Review Non-Invasive Neurostimulation Methods for Acute and Preventive Migraine Treatment—A Narrative Review Stefan Evers 1,2 1 Faculty of Medicine, University of Münster, 48153 Münster, Germany; [email protected] 2 Department of Neurology, Lindenbrunn Hospital, 31863 Coppenbrügge, Germany Abstract: Neurostimulation methods have now been studied for more than 20 years in migraine treatment. They can be divided into invasive and non-invasive methods. In this narrative review, the non-invasive methods are presented. The most commonly studied and used methods are vagal nerve stimulation, electric peripheral nerve stimulation, transcranial magnetic stimulation, and transcranial direct current stimulation. Other stimulation techniques, including mechanical stimulation, play only a minor role. Nearly all methods have been studied for acute attack treatment and for the prophylactic treatment of migraine. The evidence of efficacy is poor for most procedures, since no stimulation device is based on consistently positive, blinded, controlled trials with a sufficient number of patients. In addition, most studies on these devices enrolled patients who did not respond sufficiently to oral drug treatment, and so the role of neurostimulation in an average population of migraine patients is unknown. In the future, it is very important to conduct large, properly blinded and controlled trials performed by independent researchers. Otherwise, neurostimulation methods will only play a very minor role in the treatment of migraine. Keywords: neurostimulation; vagal nerve; supraorbital nerve; transcranial magnetic stimulation Citation: Evers, S. Non-Invasive Neurostimulation Methods for Acute and Preventive Migraine 1. Introduction Treatment—A Narrative Review. J. One of the recent innovations in migraine treatment was the detection of several types Clin. -
History, Applications, and Mechanisms of Deep Brain Stimulation
NEUROLOGICAL REVIEW SECTION EDITOR: DAVID E. PLEASURE, MD History, Applications, and Mechanisms of Deep Brain Stimulation Svjetlana Miocinovic, MD, PhD; Suvarchala Somayajula, MD; Shilpa Chitnis, MD, PhD; Jerrold L. Vitek, MD, PhD eep brain stimulation (DBS) is an effective surgical treatment for medication-refractory hypokinetic and hyperkinetic movement disorders, and it is being explored for a variety of other neurological and psychiatric diseases. Deep brain stimulation has been Food and Drug Administration–approved for essential tremor and Parkinson disease and has Da humanitarian device exemption for dystonia and obsessive-compulsive disorder. Neurostimulation is the fruit of decades of both technical and scientific advances in the field of basic neuroscience and functional neurosurgery. Despite the clinical success of DBS, the therapeutic mechanism of DBS re- mains under debate. Our objective is to provide a comprehensive review of DBS focusing on move- ment disorders, including the historical evolution of the technique, applications and outcomes with an overview of the most pertinent literature, current views on mechanisms of stimulation, and de- scription of hardware and programming techniques. We conclude with a discussion of future devel- opments in neurostimulation. JAMA Neurol. 2013;70(2):163-171. Published online November 12, 2012. doi:10.1001/2013.jamaneurol.45 Deep brain stimulation (DBS) has evolved recovery.1-4 New applications continue to as an important therapy for the treat- emerge, encouraged by past successes and ment of essential tremor, Parkinson dis- the fact that DBS effects are reversible al- ease (PD), and dystonia, and it is also lowing exploration of new targets and ap- emerging for the treatment of medication- plications not previously possible with le- refractory psychiatric disease.